Ocrevus (ocrelizumab) in India typically costs from AUD $26,168 to AUD $34,220, with the final price dependent on the dosage and clinic service fees. In Australia, the average cost for similar treatment is around AUD $18,548. Patients travelling to India can save approximately 0% while accessing international-standard care. Core treatment costs usually include the medication, specialist administration, and basic daycare facility fees at major medical hubs.
Bookimed Expert Insight: Choosing NABH-accredited centres like Manipal Hospitals or HCG Manavata Cancer Centre ensures institutional quality. Large networks use high volumes to maintain reliable supply chains for specialised biologics. Experts like Dr. Lalit Banswal at HCG Manavata specialise in advanced immunotherapy protocols. This expertise is vital for managing complex infusion reactions. Such clinics often provide integrated support that smaller pharmacies cannot match.
| India | Thailand | Turkey | |
| Ocrevus (ocrelizumab) | from AUD $26,168 | from AUD $28,756 | from AUD $14,378 |
No hidden fees – just official clinic prices. Pay at the clinic for Ocrevus (ocrelizumab) upon arrival and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Ocrevus (ocrelizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Ocrevus (ocrelizumab) journey.
The doctor graduated with a Bachelor of Medicine from Mysore University in 1996, followed by a Doctor of Medicine in radiotherapy from Banaras Hindu University in 2002. Further enhancing expertise, the doctor earned a Diplomate of National Board in radiotherapy in 2004.
The doctor is a member of several prestigious organizations, including the Association of Radiation Oncology of India, the Society for Neuro-Oncology, the Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology, reflecting a strong commitment to advancing the field of oncology.
The doctor is an experienced nuclear medicine specialist at HCG Manavata Cancer Centre with 12 years in the field. The doctor specializes in various nuclear scans, PET-CT scans, and nuclear cardiology services, demonstrating proficiency in radioiodine and Lu-177 RN therapies. Over the course of their career, the doctor has managed more than 30,000 PET scans and treated over 1,000 thyroid cancer patients. Additionally, the doctor has contributed to the field through published papers in various medical journals.
Professor Shruti Kate is the Head of Department at HCG Manavata Cancer Centre and previously served as a consultant at Tata Memorial Hospital.
Dr. Lalit Banswal is a surgical oncologist at HCG Manavata Cancer Centre in Nashik. He has successfully performed more than 10,000 major surgeries. Dr. Banswal focuses on gastrointestinal cancer and robotic surgical techniques. He completed a two-year fellowship at the Tata Medical Centre, Kolkata.